Petrelintide and ZUPREME-2
Petrelintide is an investigational long-acting amylin analog. Zealand Pharma's October 7 announcement reported positive ZUPREME-2 results from a US-based study in people with overweight or obesity and type 2 diabetes. The trial compared petrelintide with placebo, not directly with semaglutide or tirzepatide. 1
How is petrelintide different from GLP-1 drugs?
Zealand identifies petrelintide, formerly ZP8396, as an amylin analog. Its pipeline distinguishes the standalone program from a separate planned combination with CT-388. The molecule's name and development program should stay attached to the evidence being discussed. 3
Amylin and GLP-1 are different biological targets. Similar headlines about weight change do not make compounds versions of the same medicine or establish that a result for one can be transferred to another.
What was the study design?
The registry for NCT06926842 describes a randomized, double-blind, placebo-controlled Phase 2 trial. Its primary outcome was percentage body-weight change at week 28. The public record's latest posted update is September 9 and lists the study as completed. 2
The company release describes 220 participants, while the registry lists 221 actual participants. Those source figures are retained as reported; the available summaries do not establish why they differ. 1 2
What outcomes were announced?
The company reported up to 9.2% average weight reduction with petrelintide versus 2.0% with placebo at 28 weeks using the efficacy estimand. It also reported discontinuation due specifically to gastrointestinal adverse events of 1.9% versus 1.7%. Those percentages describe a particular adverse-event category, not all reasons for stopping treatment. 1
| Reported item | What it answers |
|---|---|
| Weight change at 28 weeks | The trial's defined primary assessment |
| GI-related discontinuation | Stopping treatment for gastrointestinal adverse events |
| Placebo comparison | The tested control; not a comparison with another active medicine |
| Full results still to be presented | The evidence stage described in the October announcement |
Does this establish an advantage over other peptides?
No active-drug comparison was built into ZUPREME-2. Comparing its headline percentage with a different trial would require accounting for the population, duration, background therapy and analysis. A smaller or larger number alone does not supply a head-to-head result. 2
The same caution applies to tolerability. A low percentage for one reason for discontinuation cannot be treated as a complete safety assessment or compared casually with an all-adverse-event figure from another study.
What comes after ZUPREME-2?
The company reports that Phase 3 development has started. Its pipeline still identifies petrelintide as investigational. 1 3
Later reporting should keep those trials separate and examine whether their predefined outcomes are met. Regulatory approval, availability and broad comparative claims would need their own evidence; they do not follow automatically from this Phase 2 announcement.
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.